Page 232 - Read Online

Lugaresi et al. Hepatoma Res 2018;4:67 I http://dx.doi.org/10.20517/2394-5079.2018.88 Page 9 of 9

10. Pizza G, De Vinci C, Lo Conte G, Maver P, Dragoni E, et al. Immunotherapy of metastatic kidney cancer. Int J Cancer 2001;94:109-20.
11. Bertelli R, Neri F, Tsivian M, Ruhrman N, Cavallari G, et al. Endolymphatic immunotherapy in inoperable hepatocellular carcinoma.
Transplant Proc 2008;40:1913-5.
12. Chan SL, Mok T, Ma BB. Management of hepatocellular carcinoma: beyond Sorafenib. Curr Oncol Rep 2012;14:257-66.
13. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-
90.
14. Potenza N, Mosca N, Zappavigna S, Castiello F, Panella M, et al. MicroRNA-125a-5p is a downstream effector of Sorafenib in its
antiproliferative activity toward human hepatocellular carcinoma cells. J Cell Physiol 2017;232:1907-13.
15. Stiuso P, Potenza N, Lombardi A, Ferrandino I, Monaco A, et al. MicroRNA-423-5p promotes autophagy in cancer cells and is increased in
serum from hepatocarcinoma patients treated with Sorafenib. Mol Ther Nucleic Acids 2015;4:e233.
16. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, et al. New response evaluation criteria in solid tumours: revised RECIST
guideline (version 1.1). Eur J Cancer 2009;45:228-47.
17. Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, et al. Molecular targets and oxidative stress biomarkers in hepatocellular
carcinoma: an overview. J Transl Med 2011;9:171.
18. Cannistrà M, Ruggiero M, Zullo A, Gallelli G, Serafini S, et al. Hepatic ischemia reperfusion injury: a systematic review of literature and
the role of current drugs and biomarkers. Int J Surg 2016;33:S57-70.
19. Lo Re O, Panebianco C, Porto S, Cervi C, Rappa F, et al. Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity
of Sorafenib in hepatocellular cancer cells. J Cell Physiol 2018;233:1202-12.
20. Onishi S, Saibara T, Fujikawa M, Sakaeda H, Matsuura Y, et al. Adoptive immunotherapy with lymphokine activated killer cells plus
recombined interleukin 2 in patients with unresectable hepatocellular carcinoma. Hepatology 1989;10:349-53.
21. Lai CL, Lau JY, Wu PC, Ngan H, Chung HT, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized
controlled trial. Hepatology 1993;17:389-94.
22. Berretta M, Di Francia R. The real impact of target therapy in cancer patients: between hope and reality. Curr Cancer Drug Targets
2018;18:402-4.